Comparison of faster-acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery

Diabetes Obes Metab. 2023 Apr;25(4):1121-1124. doi: 10.1111/dom.14942. Epub 2022 Dec 27.

Authors

Hood Thabit^{1

2}, Womba Mubita¹, Jose Rubio¹, Mini Karuppan¹, Jonathan Schofield^{1

2}, Malgorzata E Willinska³, Roman Hovorka³, Lalantha Leelarathna^{1

2}

Affiliations

¹ Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
² Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
³ Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

PMID: 36514847
DOI: 10.1111/dom.14942

No abstract available

Keywords: CSII; clinical trial; continuous glucose monitoring; insulin analogues; insulin pump therapy; insulin therapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 1* / drug therapy
Humans
Hypoglycemic Agents / therapeutic use
Insulin / therapeutic use
Insulin Aspart / therapeutic use
Insulin Infusion Systems
Insulin, Regular, Human / therapeutic use

Substances

Insulin Aspart
Insulin
Blood Glucose
Hypoglycemic Agents
Insulin, Regular, Human

Associated data

ClinicalTrials.gov/NCT03579615